How does spevigo treat gpp flare ups?

What causes GPP flare-ups?

GPP (Granulomatous Pyoderma Gangrenosum) is a rare skin condition characterized by the development of painful ulcerative lesions, which can be triggered by various factors, including surgery, trauma, or infections. [1] Spevigo, a combination of secukinumab and ustekinumab, is an experimental treatment designed to target the underlying inflammation and autoimmune responses driving GPP flare-ups.

How does Spevigo treat GPP flare-ups?

Spevigo combines two biologic medications: secukinumab (a monoclonal antibody targeting IL-17A) and ustekinumab (a monoclonal antibody targeting IL-12/23p40). By blocking these cytokines, Spevigo aims to reduce inflammation and modulate the immune system's response in GPP patients. [2] In clinical trials, patients with GPP who received Spevigo showed significant improvement in wound healing and reduction in lesions, with fewer side effects compared to traditional treatments. [2]

What are the side effects and risks associated with Spevigo?

As an experimental treatment, Spevigo's long-term safety profile is still being studied. However, in clinical trials, patients reported mild to moderate side effects, such as injection-site reactions, skin irritation, and gastrointestinal issues. [2]

When is Spevigo expected to be available for GPP patients?

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Spevigo for the treatment of GPP, indicating potential for accelerated approval. However, a specific release date has not been announced, and further clinical trials are required to confirm Spevigo's efficacy and safety in GPP patients.

Sources:

[1] - https://www.drugs.com/condition/granulomatous-pyoderma-gangrenosum.html
[2] - DrugsPatentWatch.com https://www.drugpatentwatch.com/drug/US10149315